Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (avastin)
Tuesday, October 29, 2013 - 13:30
in Health & Medicine
A study published shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab’s blockage of VEGF-A to continue to drive tumor growth.